BERWYN, PA — Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., is set to present groundbreaking data on its LACRIFILL® Canalicular Gel during the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Los Angeles from April 25-28. The company will share case studies and patient feedback that underline the effectiveness of this innovative dry eye treatment.
Recent findings, published in Cataract & Refractive Surgery Today, demonstrated how the gel significantly enhances visual acuity and optical quality, particularly in patients experiencing fluctuating vision post-cataract surgery. The therapy utilizes lacrimal occlusion to address dry eye symptoms and improve outcomes. Additionally, a Patient Experience survey revealed an overwhelming 98.11% satisfaction rate among users, with nearly all respondents indicating their intent to return for future doses.
“One year after launching at ASCRS 2024, we have case studies and patient experience data showing how LACRIFILL Canalicular Gel, our interventional dry eye treatment, is changing practice and changing lives,” said Jai Parekh, Chief Commercial Officer of Eye Care U.S. “It’s exciting to share these proven results with this year’s attendees, who aim to bring the latest innovations to their patients.”
Priya Mathews, MD, from the Center for Sight, also highlighted the gel’s impact. “I’m delighted to be one of the MDs sharing my experience and patient outcomes with LACRIFILL Canalicular Gel and the practice benefits of becoming a ‘Lacrifiller’ with attendees,” she said.
Nordic Pharma invites ASCRS attendees to visit booth #717 to learn more about LACRIFILL Canalicular Gel’s clinical benefits and patient-centric success. The therapy’s growing recognition further underscores its role in advancing solutions for dry eye care.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.